Cosmetic cross-reference Noindex: medium evidence

Platinum

CAS 7440-06-4

Platinum (CAS 7440-06-4) is a pharmaceutical compound with 0 bioactivity targets and 33 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral / FAERS
Adverse signals
33
SOURCE IUPHAR / PharmGKB
PubMed IDs
14
SOURCE EPA DSSTox

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Platinum
CAS Number
7440-06-4
Molecular Formula
Pt
InChIKey
BASFCYQUMIYNBI-UHFFFAOYSA-N
Source Match
EPA DSSTox
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE DSSTox identifiers same-CAS cross-reference

Cross-Reference to Chemicals

Same-CAS substance identity is available in the industrial chemicals vertical.

Platinum is linked through DSSTox identifiers.

View industrial chemical data →
SOURCE PharmGKB drug-gene phenotypes 56 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

C18orf56 (PA134956204),"TYMS (PA359)" rs45445694
-
Evidence: -; PMID 25677447
ABCB1 (PA267) rs2032582
-
Evidence: -; PMID 19203783
ERCC1 (PA155) rs11615
-
Evidence: -; PMID 19362955
XRCC1 (PA369) rs25487
-
Evidence: -; PMID 19362955
ERCC1 (PA155) rs3212986
-
Evidence: -; PMID 19362955
ERCC5 (PA27851) rs17655
-
Evidence: -; PMID 22158331
ERCC5 (PA27851) rs17655
-
Evidence: -; PMID 22158331
POU2F2 (PA33537) rs195862
-
Evidence: -; PMID 24643204
POU2F2 (PA33537) rs2444933
-
Evidence: -; PMID 24643204
POU2F2 (PA33537) rs3823036
-
Evidence: -; PMID 24643204
POU2F2 (PA33537) rs195854
-
Evidence: -; PMID 24643204
AQP2 (PA24920) rs3759125
-
Evidence: -; PMID 24643204
AQP2 (PA24920) rs10875989
-
Evidence: -; PMID 24643204
AQP9 (PA24927) rs1867380
-
Evidence: -; PMID 24643204
TMEM205 (PA162406385) rs7251786
-
Evidence: -; PMID 24643204
TMEM205 (PA162406385) rs896412
-
Evidence: -; PMID 24643204
LRP1 (PA233) rs1057451
-
Evidence: -; PMID 24643204
LRP1 (PA233) rs4788186
-
Evidence: -; PMID 24643204
LRP1 (PA233) rs7204252
-
Evidence: -; PMID 24643204
LRP1 (PA233) rs4788184
-
Evidence: -; PMID 24643204
RICTOR (PA165660455) rs7719775
-
Evidence: -; PMID 27676404
RICTOR (PA165660455) rs7703002
-
Evidence: -; PMID 27676404
AQP9 (PA24927) rs1516400
-
Evidence: -; PMID 24643204
AQP9 (PA24927) rs1554203
-
Evidence: -; PMID 24643204
RICTOR (PA165660455) rs6878291
-
Evidence: -; PMID 27676404
ERCC5 (PA27851) rs17655
-
Evidence: -; PMID 28314991
AQP2 (PA24920) rs10875989
-
Evidence: -; PMID 26358256
XRCC5 (PA37425) rs1051685
-
Evidence: -; PMID 26358256
AQP2 (PA24920) rs3759125
-
Evidence: -; PMID 26358256
AQP2 (PA24920) rs7305534
-
Evidence: -; PMID 26358256
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Platinum used for in pharmaceutical contexts?

Platinum (CAS 7440-06-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Platinum?

Platinum has 33 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Adrenal insufficiency, Adverse event, Alanine aminotransferase increased, Anaemia, Aspartate aminotransferase increased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Platinum also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Platinum with EU status "restricted".

What clinical phase is Platinum in?

No phase 1-4 clinical development badge is rendered for Platinum because the matched compound identifier rows do not contain a max-phase value.